
==== Front
Orphanet J Rare Dis
Orphanet J Rare Dis
Orphanet Journal of Rare Diseases
1750-1172
BioMed Central London

3333
10.1186/s13023-024-03333-4
Research
Health service utilization, economic burden and quality of life of patients with mucopolysaccharidosis in China
Kang Qi 1
Fang Yuhang 2
Yang Yan 1
Li Dingguo 3
Zheng Lin 4
Chen Xinyi 5
http://orcid.org/0009-0002-4122-4951
Tu Xiaowen tuxwcn@163.com

2
Jin Chunlin jinchunlin@shdrc.org

1
1 grid.508184.0 0000 0004 1758 2262 Shanghai Health Development Research Center (Shanghai Medical Information Research Center), Shanghai, China
2 Shanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Laboratory of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China
3 Shanghai Foundation for Rare Disease, Shanghai, China
4 grid.47187.3d 0000 0004 0368 9544 Beijing Zhengyu MPS Care Center for Assistance, Beijing, China
5 https://ror.org/00z27jk27 grid.412540.6 0000 0001 2372 7462 Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
6 9 2024
6 9 2024
2024
19 3247 11 2023
21 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Patients with mucopolysaccharidosis (MPS) often face delayed diagnoses, limited treatment options and high healthcare costs, that may significantly affect patients' quality of life. The objective of this study was to understand medical service utilization related to diagnosis and treatment, economic burden during diagnosis period, and health-related quality of life among MPS patients in China.

Methods

A series of patients diagnosed with MPS registered in the national patient organization were recruited for a cross-sectional survey from May to July 2019. Information were collected from patients or their parents via phone interview, including demographic data, utilization of services related to diagnosis and treatment, total cost during the period of MPS diagnosis and health-related quality of life (HRQoL). HRQoL was assessed by PedsQL 4.0 Generic Core Scale (PedsQL) and 36-item short-form health survey (SF-36) depending on the age of patients with MPS and compared with the general Chinese population.

Results

A total of 180 MPS patients (50, 67, 15, 46, 1 and 1 for type I, II, III, IV, VI and VII), with a mean age of 9.54 years and 137 (76.11%) males, were included in analysis. The mean age at first visit to a medical doctor for MPS related symptoms was 3.65 ± 2.58 years old, while only 12 patients (6.67%) were diagnosed on their first visit. The mean diagnostic delay, which is defined as the time between the first visit to a medical doctor for MPS related symptoms and the final diagnosis, was 9.42 months, with no significant difference between types. The average number of misdiagnosis was 4.56. Before the confirmed diagnosis, the patients made an average of 6.31 visits and visited 4.3 hospitals. During diagnosis period, the mean of ¥81,086.72 direct medical costs accounted for 63.75% of the total cost. Only 32.78% of the patients had ever received specific treatments. The mean scores of PedsQL and SF-36 of patients were significantly lower than the Chinese norms. Household annual income per person, specific treatment use and MPS subtype were significantly associated HRQoL of patients.

Conclusion

The results highlight challenges faced by MPS patients in terms of diagnosis, access to specific treatments, economic burden and low HRQoL. There is an urgent need to improve early detection and diagnosis, create fair and consistent mechanisms to increase access to specialized treatment and reduce the economic burden of MPS patients in China.

Keywords

Mucopolysaccharidosis
Diagnoses
Treatment
Economic burden
Health-related quality of life
Rare disease
Health Young Talent Program from Shanghai Health Commission2022YQ058 Kang Qi issue-copyright-statement© Institut National de la Santé et de la Recherche Médicale (INSERM) 2024
==== Body
pmcIntroduction

Mucopolysaccharidosis (MPS) is the most common type of lysosomal storage disorders (LSDs) caused by autosomal recessive defects, which are characterized by a natural deficiency in the enzymes that break down glycosaminoglycans (GAGs) [1–3]. Based on the specific enzyme deficiency present, MPS are categorized into seven distinct clinical types, described as MPS I through MPS IX (excluding MPS V and VIII), and some types are further categorized into subtypes [4]. MPS can lead to a range of symptoms and health problems, including skeletal abnormalities, developmental delays, vision and hearing loss, heart problems, and neurological complications [2]. The estimated incidence of MPS ranges from 1.04 to 4.8 in 100,000 live births worldwide, with some types being more common in some populations and ethnic groups due to consanguineous marriages and other factors [4–6]. For instance, the incidence rate of MPS in the United States was 0.98 per 100,000 live births, with the common types being MPS I, II, and III (accounted for 26%, respectively) [7]; while it was 2.04 per 100,000 live births in Taiwan, with MPS II accounted for 52.3%, MPS I accounted for 5.4%, MPS III accounted for 19.2% [8]. Eastern China is also dominated by MPS II (47.4%), followed by MPS IVa (26.8%), MPS I (16.3%), MPS VI (4.2%), MPS III (4.2%) and MPS VII (1.1%) [3].

MPS is a genetic chronic disease that can occur from the fetal period to adolescence. Diagnosis delay in MPS patients is widespread due to lacking early specificity [9–13]. A Dutch study showed that the diagnostic delay for patients with MPS I and MPS III had not shorten between 1988 and 2017 [10]. Patients with delayed diagnosis do not receive timely treatment, which in turn leads to irreversible clinical features, multiple organ damage [4, 14], reduced quality of life [15–17], and increased additional medical costs [17].

The specific therapies of MPS include enzyme replacement therapy (ERT), hematopoietic stem cell transplantation (HSCT), and gene therapy. ERT directly introduces functional enzymes into the body to reduce or normalize GAG levels [18–23]. HSCT and gene therapy are considered permanent treatments. HSCT involves the transplantation of cells from bone marrow, peripheral blood, or umbilical cord blood, which penetrate throughout the body's tissues and organs to produce degrading enzymes to alleviate symptoms [24]; gene therapy is not limited by donor or blood–brain barrier restrictions but may cause rejection of gene products [25]. However, specific treatments are expensive [26, 27] and may be not covered by national health insurance [28, 29], which places a heavy economic burden on patients [30, 31]. As a consequence, the accessibility of specific treatments and health-related quality of life (HRQoL) for patients with MPS would be negatively affected.

Overall, MPS has an early onset in both developed and developing countries, with a long diagnostic delay in most patients [10–12, 32, 33]. After diagnosis, the use of specific treatments such as ERT is low, especially in developing countries [9, 28, 34, 35]. Ultimately, HRQoL of MPS patients is severely impaired, both in physical and psychological, and is much lower than that of the general population [32, 36–38]. However, previous studies have focused on a single type of MPS [9, 32, 34–36, 38–40] or discussed MPS within the broad category of LSDs [28] with small sample sizes. In addition, although studies have suggested that delay in diagnosis increases pre-diagnosis health care costs [17], the exact economic burden is unclear. The objective of this study was to understand medical service utilization, assess the economic burden during diagnosis period and HRQoL, and explore factors influencing HRQoL among MPS patient in China.

Methods

Study design

This was a nationwide cross-sectional study aimed to investigate the survival status and disease burden of MPS patients in China. It was based on a convenience sample because MPS patients are scattered and no sampling frame is available in China. All MPS patients that were recruited for the study are registered in Beijing Zhengyu MPS Care Center (BZ-MPSCC) which was established in 2012—the only national patient organization providing services related to medical treatment and rehabilitation to MPS patients. The survey was carried out via phone calls by trained interviewers from Livingston Market Consultants (LMC), an independent market research and consultant company using a structured questionnaire between May and July 2019. The questionnaire was designed by Shanghai Health Development Research Center (SHDRC), BZ-MPSCC and LMC, based on a literature review and interviews with doctors, health economy and policy researchers in the field of rare diseases. Informed consent was obtained from patients and their guardians. The study was approved by the Medical Ethics Committee of SHDRC.

Inclusion criteria

Patients who met all the following conditions were recruited: (i) They were diagnosed in the hospital with specific type of MPS, including type I, II, III, IV, VI or VII; (ii) The patients or their primary caregivers were willing to participate in the survey and were able to complete the questionnaire. Among 378 patients registered in BZ-MPSCC, 180 of them completed the survey. Since most of the patients were children and adolescents, 170 questionnaires were answered by their parents. The other 10 patients who were above 21 years old conducted interview with the help from their parents.

Measurements

Health service utilization

The measures of health service utilization covered utilization of service related to diagnosis and treatment including age (year/month) at initial visit and confirmed diagnosis, types of hospital visited as well as number of visits, misdiagnoses, and hospitals visited, treatment after diagnosis (Without any treatments/Only symptomatic treatment, including orthopaedic surgery, heart valve replacement, corneal transplantation, physical therapy, etc./Only specific treatment, including ERT, HSCT and gene therapy/Both symptomatic and specific treatment).

Cost during the diagnostic period

In this study, we conducted a retrospective assessment of the total cost during the period of MPS diagnosis, which encompassed direct healthcare costs, direct non-healthcare costs, and indirect costs incurred by patients and their families. Costs comprised the following components: Direct healthcare costs: (i) laboratory and test costs; (ii) treatment and surgical costs; (iii) drugs’ costs; (iv) costs of nursing, rehabilitation or physiotherapy; Direct non-healthcare costs: (v) transportation costs, including expenses for aircraft, trains, taxi, and public transportation; (vi) accommodation costs, including hotels, rents due to visits; (vii) health care, nutritional supplementation; Indirect costs: (viii) daily lost wages; (ix) other indirect costs. For the purpose of comparison, the exchange rate is based on 1 USD ($) = 7 CNY (¥).

HRQoL

The PedsQL 4.0 Generic Core Scale (PedsQL), originally developed by Varni, was used to assess HRQoL of children aged 2 to 18 [41]. The Chinese version also has good reliability and validity [42]. The PedsQL scale evaluates HRQoL across four dimensions: physical functioning (8 items), emotional functioning (5 items), social functioning (5 items), and school functioning (5 items). The psychosocial health dimension comprises the emotional, social, and school functioning subscales. For each item, a five-point response scale was used (0 ~ 4, never a problem ~ always a problem). Items were reverse-scored and converted to a hundred mark system (0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0), so that higher scores indicated better HRQOL.

The 36-item short-form health survey (SF-36) was used to evaluate the HRQoL of adolescents aged 16 years and above. The scale was revised by Ware and Sherbourne based on the RAND Corporation's Health Insurance and has been translated, localized, and validated in China [43–45]. The scale includes eight dimensions: physical functioning (PF), role limitations due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role limitations due to emotional problems (RE), and mental health (MH). Each dimension scores were calculated by summing across items in the same dimension and convert to a 0–100 scale, with higher scores indicating better health status [46].

Statistics analysis

Descriptive analysis was carried out using mean and standard deviation (SD) for continuous variables and proportions for dichotomous or categorical variables. Analysis of variance and chi-square tests were used for comparison between groups, and linear regression model was used to explore factors associated with HRQoL. All analysis was carried out with Stata SE 15.0 (StataCorp LLC, College Station, TX, USA).

Results

Sample characteristics

The average age of participants with MPS in this study was 9.54 ± 6.02 years, with a majority being younger than 10 years old (63.89%), male (76.11%), and from the eastern (44.59%) and central (33.76%) regions of China. More than seventy percent (72.23%) of them had a household annual income per person of less than ¥20,000 ($2857.14). The most common type of the patients was type II (37.22%), followed by type I (27.78%) and type IVa (25.56%) (Table 1).Table 1 Demographic characteristic of the study participants

Variables	N	%/Mean ± SD	
Region	
 East	82	45.56	
 Central	59	32.78	
 West	34	18.89	
 Northeast	5	2.78	
Sex	
 Male	137	76.11	
 Female	43	23.89	
Age (years)	180	9.54 ± 6.02	
 0 ~ 	38	21.11	
 5 ~ 	77	42.78	
 10 ~ 	40	22.22	
 ≥ 15	25	13.89	
Annual household income per capita (¥)	
 < 10,000	64	35.56	
 10,000 ~ 	66	36.67	
 20,000 ~ 	19	10.56	
 ≥ 30,000	31	17.22	
Type of MPS	
 Type I	50	27.78	
 Type II	67	37.22	
 Type III/VI/VII*	17	9.45	
 Type IVa	46	25.56	
Total	180	100.00	
*Number of type III, type VI and type VII is 15, 1 and 1, respectively

Diagnosis and treatment service utilizations

As shown in Table 2, the average age at first visit to a medical doctor for MPS related symptoms for type II (4.23 years) and type IVa (4.24 years) patients were more than one year later than type I (3.13 years) and type III /VI/VI patients (3.13 years). The average age at confirmed diagnosis was 4.15 years old (3.59 years, 4.93 years, 5.10 years and 3.27 year for type I, type II, type IVa and type III/VI/VI, respectively). It took 9.42 months on average for the diagnosis to be confirmed, and over 20% of patients took more than one year to be diagnosed, with no significant difference between types. Prior to the confirmed diagnosis, MPS patients made an average of 6.31 visits and visited 4.3 hospitals. The average number of misdiagnosis was 4.56 (5.34, 3.27, 4.60 and 6.60 for type I, type II, type IVa and type III/VI/VI, respectively), with significant difference between types (F = 3.73, p = 0.013).Table 2 Diagnosis and treatment service utilizations

Variables	N	%/Mean ± SD	F/Χ2	p-value*	
Age at first visit (years)	178	3.65 ± 2.58	2.75	0.045	
Age at diagnosis (years)	132	4.15 ± 3.22	2.61	0.054	
Diagnostic delay (months)	132	9.42 ± 20.98	0.17	0.919	
 0	12	9.09			
 < 1	63	47.73			
 1 ~ 6	23	17.42			
 7 ~ 12	7	5.30			
 > 12	27	20.45			
Diagnosed at first visit	180	6.67	5.07	0.167	
 Level III pediatric hospital	95	6.32			
 Level III general hospital	62	8.06			
 Overseas hospitals	3	33.33			
 Others	20	0.00			
Number of visits before diagnosed	143	6.31 ± 6.85	0.90	0.445	
Number of hospitals before diagnosed	143	4.30 ± 5.59	0.50	0.683	
Number of misdiagnoses	143	4.56 ± 4.01	3.73	0.013	
Treatments			6.55	0.684	
 Without any treatments	9	5.00			
 Only symptomatic treatment	112	62.22			
 Only specific treatment	43	23.89			
 Symptomatic & specific treatment	16	8.89			
*Comparison between subtypes

Only one third of the patients (32.78%) had ever received specific treatments: 22.78% of them received HSCT, 11.67% ERT, and 0.56% gene therapy. The main reasons for not receiving ERT were “the costly burden of treatment” (51.59%), “it was not available” (26.75%), “missed optimal treatment timing” (6.37%); and for HSCT were “the costly burden of treatment” (18.98%), “the doctor didn't think it was necessary” (18.98%), “missed optimal treatment timing (17.52%), “worried about the treatment risks” (15.33%), and “worried about the feasibility of the treatment” (11.68%).

Economic burden during diagnosis period

The average total cost for patients during diagnosis period was ¥127,196.72 ($18,170.96). Overall, direct medical costs accounted for a higher proportion (63.75%) than direct non-medical costs (20.72%) and indirect costs (15.53%). Of the direct cost, the highest cost was nursing/rehabilitation/physical therapy (¥30,335.56/$4333.65, 37.41% of the direct medical costs), and health care/nutrition supplement was the highest direct non-medical costs (¥10,808.33/ $1544.05, 41.02% of the direct non-medical costs). The costs of daily lost wages (¥16,269.44/$2324.21) accounted for 82.34% of the indirect costs (Table 3).Table 3 Costs per person before diagnosis (n = 180)

Variables	Mean ± SD (¥)	% Category of cost	% Total cost	
Direct medical costs	81,086.72 ± 122,966.34	100.00	63.75	
 Medical tests	17,207.22 ± 12,897.76	21.22	13.53	
 Surgery	15,023.33 ± 40,172.97	18.53	11.81	
 Drugs	18,520.61 ± 48,665.80	22.84	14.56	
 Rehabilitation/nursing	30,335.56 ± 56,193.81	37.41	23.85	
Direct non-medical costs	26,350.56 ± 31,043.45	100.00	20.72	
 Transportation	8162.22 ± 11,161.88	30.97	6.42	
 Accommodation	7380.00 ± 11,208.53	28.01	5.80	
 Health care/nutrition	10,808.33 ± 18,083.64	41.02	8.50	
Indirect costs	19,759.44 ± 30,756.90	100.00	15.53	
 Daily lost wages	16,269.44 ± 27,091.78	82.34	12.79	
 Other costs	3490.00 ± 11,277.78	17.66	2.74	
Total costs	127,196.72 ± 158,126.60	100.00	100.00	

HRQoL of patients

Table 4 shows that the HRQoL of MPS patients was lower than the Chinese norms [42, 47]. For those aged 2–15, patients had significantly lower score than the Chinese norm in all dimensions (p < 0.001) [42]. For those aged ≥ 16, the scores in all dimensions except for GH were also considerably lower than the Chinese national norm (p < 0.001) [47].Table 4 Quality of life of MPS patients: comparison to healthy normative sample

Domains	Patients	Normative	p-value	
PedsQL (2-15Y, n = 158)	
 Physical health	29.17 ± 25.02	88.29 ± 11.39	< 0.001	
 Psychological health	35.17 ± 21.51	82.99 ± 12.70	< 0.001	
 Emotional functioning	47.03 ± 22.52	79.39 ± 17.71	< 0.001	
 Social functioning	32.56 ± 25.27	86.94 ± 15.30	< 0.001	
 School functioning	25.91 ± 24.78	82.71 ± 14.55	< 0.001	
 Total scale	33.08 ± 20.25	84.94 ± 10.88	< 0.001	
SF-36 (≥ 16Y, n = 19)	
 Physical function (PF)	35.00 ± 25.66	87.92 ± 16.98	< 0.001	
 Role physical (RP)	35.53 ± 39.37	77.50 ± 34.86	< 0.001	
 Bodily pain (BP)	51.32 ± 32.78	82.22 ± 16.98	< 0.001	
 General Health (GH)	60.00 ± 14.04	62.51 ± 17.88	0.508	
 Vitality (VT)	52.37 ± 19.25	68.17 ± 17.63	< 0.001	
 Social function (SF)	41.45 ± 22.84	80.67 ± 19.98	< 0.001	
 Role emotional (RE)	36.84 ± 42.88	67.86 ± 39.44	< 0.001	
 Mental health (MH)	53.26 ± 19.23	68.47 ± 16.90	< 0.001	

Factors associated with PedsQL score

Household annual income per person, specific treatment use, and MPS type are important predictors of PedsQL scores. Compared with patients whose household annual income ≥ ¥30,000 per person, PedsQL scores decreased by 14.92 (p = 0.003) in patients with annual household income < ¥10,000 CNY/person and by 10.46 (p = 0.129) in patients with ¥10,000 ~ 20,000/person. MPS patients who received ERT only (β = 13.15, p = 0.028) or HSCT/gene therapy (β = 10.16, p = 0.009) had significantly higher PedsQL scores than those who did not receive specific treatments. In term of types of MPS, the PedsQL scores of Type I (β = − 13.07, p = 0.003) and Type III/VI/VII (β = − 11.57, p = 0.045) were significantly lower than those of Type IVa. Age, gender, and region were not significantly associated with PedsQL scores (Table 5).Table 5 Factors associated with PedsQL score (n = 156)

Variables	β (95% CI)	SE	Z	p-value	
Region	
 Central	− 2.36 (− 9.39, 4.67)	3.59	− 0.66	0.511	
 West	0.81 (− 7.72, 9.34)	4.35	0.19	0.852	
 Northeast	− 14.34 (− 33.67, 4.99)	9.86	− 1.45	0.146	
 East	Ref				
Sex	
 Male	− 2.22 (− 10.06, 5.63)	4.00	− 0.55	0.580	
 Female	Ref				
Age (Year)	
 2 ~ 	− 1.92 (− 11.10, 7.27)	4.68	− 0.41	0.683	
 5 ~ 	0.72 (− 6.38, 7.82)	3.62	0.20	0.843	
 10 ~ 	Ref				
Average household income (￥)	
 < 10,000	− 14.92 (− 24.71, − 5.13)	5.00	− 2.99	0.003	
 10,000 ~ 	− 10.46 (− 19.87, − 1.05)	4.80	− 2.18	0.029	
 20,000 ~ 	− 9.85 (− 21.80, 2.09)	6.09	− 1.62	0.106	
 ≥ 30,000	Ref				
MPS subtype	
 Type I	− 1.52 (− 10.22, 7.19)	4.44	− 0.34	0.733	
 Type II	− 13.21 (− 21.54, − 4.89)	4.25	− 3.11	0.002	
 Type III/VI/VII	− 15.29 (− 26.05, − 4.54)	5.49	− 2.79	0.005	
 Type IVa	Ref				
Treatment	
 Only ERT	13.15 (1.42, 24.89)	5.99	2.20	0.028	
 HSCT/Gene therapy	10.16 (2.59, 17.74)	3.87	2.63	0.009	
 Without specific treatment	Ref				

Discussions

This is a large sample study to profile the medical service utilization, disease burden and HRQoL of patients with all subtypes of MPS in China. The findings of this study show challenges faced by patients with MPS in China, including diagnostic delay, limited access to specific treatments, high economic burden prior to confirmed diagnosis and low HRQoL.

MPS has an early age of onset [9–11, 14, 32–35, 38, 39]. In this study, the mean age at first visit to a medical doctor for MPS related symptoms was 3.65 years. However, obvious diagnosis delay is observed in this study. The mean age at confirmed diagnosis was 4.15 years, which was 9.4 months on average from the first visit to a medical doctor. The length of diagnosis delay in this study (median: < 1 months) is shorter than that reported in Indian MPS patients (median: 39.5 months) [11], and Dutch MPS type I and type III patients (type I median: 9 months, type III median: 33 months) [10]. One reason might be that parents of the patients in the study were more active in seeking health services. The other reason might be that the waiting time to see a specialist in Chinese health service system is shorter because patients in China use self-scheduling services in a hospital to make an appointment but not referral services between all levels of the health system used in other countries [48].

The possible reason for the diagnostic delay is that doctors lack awareness of rare diseases [11, 49]. Among patients diagnosed at first visit in this study, all of them were diagnosed in level III hospitals located at provincial capitals and municipalities (e.g., Beijing and Shanghai). However, even in level III hospitals, the proportion of diagnosed at first visit was only 7%. In this study, the average number of misdiagnosis for MPS patients was more than 4 times. Patients had to visit more than 4 hospitals to have the final diagnosis, which further increases the time period to confirmed diagnosis and leads to a high pre-diagnosis economic burden. Kuiper et al. reported that the diagnostic delay was shorten after first visits to medical specialist but not general practitioner [10].

We fail to find any study that reported the cost for MPS patients during diagnosis period. In this study, the average per person cost for diagnosis was as high as ¥127,196.72 ($18,170.96), which is higher than the per capita disposable income of Chinese residents in 2022 (¥36,883/$5,179.47) [50]. It is worth noting that to improve the diagnosis and treatment capabilities and ensure the accessibility of drugs for rare diseases in China, a three-level National Network to Collaborate on Diagnosis and Treatment of Rare Diseases (NCDTRD) was established by the Chinese government in 2019, comprising 324 hospitals nationwide, including 1 leading national institution, and 32 leading provincial institutions [49], which will be helpful to improve diagnostic delays for Chinese MPS patients. Based on the experiences from other countries, further actions should be taken by government and medical community, including building regional specialistic centers of LSD or MPS, strengthening multidisciplinary diagnosis and treatment, improving diagnosis and treatment guidelines and educating specialists [51].

Specific treatments utilization for MPS patients in this study (32.78%) was lower than that reported in European MPS VII patients (53.8%) [9] and American MPS I patients (44%) [35]. The main reasons for low utilization of specialized treatment were low availability and affordability. Although many ERT drugs for MPS was on the market in US, EU and Japan before 2019, only two drugs were included in the List of the First Batch of Overseas New Drugs Urgently Needed in Clinical Settings issued by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in November 2018 and only one drug was authorized for marketing in May 2019 in China [46]. According to the 2022 China Rare Disease Industry Observation Report, the annual ERT costs range from ¥450,000 ($64,285.71) to ¥2,300,000 ($328,571.43) per person [27]. None of the ERT drugs for MPS has been included in the National Health Insurance Reimbursement Catalog (NHIRC), however, and only a few provinces or municipalities have formulated reimbursement policy for expensive ERT drugs for rare diseases [27, 28]. For example, Shanghai Municipality had included ERT (MPS I/II/VI) and HSCT in the Shanghai Children's Hospitalization Mutual Aid Fund since 2011, reimbursing ¥100,000/year per person [52]; and launched a citywide commercial supplemental medical insurance (one-year period) since 2021, reimbursing ERT drugs for MPS II/IVa at 70%, with a reimbursement ceiling of ¥1,000,000/person [53]. In addition, unaffordable out-of-pocket costs after reimbursement, difficulties and delays in reimbursement processes, and limited financial assistance from government or charity continue to prevent MPS patients from accessing specific treatments [28, 31, 51]. With the exception of some developed countries, more and more developing countries have included ERT in the national reimbursement system [54–56]. Further efforts are urgently needed to increase availability and affordability to specialized treatment for MPS patients by government and society in China.

MPS is a complex, progressive, and multi-system LSD. Due to diagnostic delay and unaffordability of high medical costs, about 67% of Chinese MPS patients have difficulty in controlling disease progression and develop irreversible symptoms such as skeletal deformities, hepatosplenomegaly, sensory deficits, and cardiac disease, significantly reducing their HRQoL [4, 9]. Not surprisingly, the HRQoL of MPS patients was significantly lower than that of the general population for almost all dimensions of the PedsQL or SF-36 covering physiological, psychological, and social aspects in this study, which is in line with other studies [33, 39]. The low HRQOL in MPS patients might attribute to multiorgan involvement and trajectory of cognitive decline in some types of MPS. The low score on physiological dimensions (i.e., difficulty doing daily activity, physical pain, and low energy) is likely a direct consequence of the disease manifestations, while the low score on psychological and social dimensions may be impacted on a secondary level for MPS patients [34]. In terms of social function, for example, Meijer [57] found that physical limitations and pain in chronically ill children were associated with a lower level of social activities. Besides, differences in physical appearance and basic self-care and communication skills between MPS patients and their healthy peers could lead to teasing or social isolation [34], which would have further negative impact on their social function.

Consistent with the findings from previous rare disease studies [58, 59], we found that low household economic level was significantly associated with lower HRQoL of MPS patients in this study. The reason might be that higher-income families have more access to social support, quality healthcare and specialty care [58, 59]. Efforts to improve the household economic status of MPS patients would guarantee better HRQoL for them. Similar to findings from other rare disease studies [60, 61], significant differences in HRQoL between subtypes of MPS was observed in this study. Compared with MPS IVa, MPS II and III/VI/VII patients were more likely to have low HRQoL. According to previous studies, the number and severity of disease symptoms is negative associated with HRQoL [39]. The difference in disease severity and cognitive impairment between subtypes might be contributed to type differences in HRQoL. For example, MPS III patients tend to have severe neurological system lesions with rapidly progressive symptoms including cognitive decline, idiopathic developmental delay, hyperactivity, and sleep disorder [4, 62], patients with MPS VI present with severe clinical symptoms in the neonatal period [63], and patients with the severe form of MPS II also present central nervous symptoms rapidly and tend to die in the first decade of life without effective treatment [4].

In line with previous studies [32, 34], we found that specific therapeutic use was associated with higher HRQoL. ERT and HSCT can normalize the concentration of GAGs in the target organ and improve organomegaly, pain, airway obstruction, corneal clouding, hearing, and motor function. Clinical trials have demonstrated the efficacy of ERT and HSCT for MPS I, II, IV, VI, and VII, with better outcomes for a combination of HSCT and ERT [4, 64]. Unfortunately, both HSCT and ERT have proven unsatisfactory in patients with MPS III because MPS III is a special type of MPS that primarily affects central nervous system. Gene therapy is important options for MPS III to improve outcomes. However, such specific treatments do not affect irreversible lesions such as short stature, neurological lesions, and vascular malformations [64, 65]. Early diagnosis and early initiation of specific treatment is believed to be key in improving clinical- and patients-reported outcomes and patient quality of life [2, 66], especially for subtypes with rapid progression. During treatment period, it is essential for MPS patients to timely receive adequate ERT to improve symptom and prolong life.

In addition, rehabilitation for MPS patients played an important role in managing disabilities and quality of life [2, 56, 67, 68]. Dusing et al. recommended that children diagnosed with MPS type I be referred to rehabilitation services at the time of diagnosis [69]. Cibele et al. recommended that otorhinolaryngologist should be part of the group of professionals that follows MPS patients to better monitor their hearing and provide early hearing rehabilitation [70]. Because of several serious complications, a multidisciplinary treatment and rehabilitation team, life-long therapies and life-cycle management of patients with MPS should be implemented and emphasized.

Limitations

Firstly, the study was based on a convenience sample due to lack of a national statistical surveillance network. Thus, the findings may not be generalized to all. However, this is the largest sample study covering all types of MPS in China. Secondly, self-reported data obtained through a questionnaire on health service utilization and cost during the diagnostic period are inevitably subject to recall bias. Thirdly, due to small sample size, we failed to compare MPS type III, VI and VII individually and explore factors associated with HRQoL among patients over 15 years, which needs to be further explored in the future. Finally, results from this cross-sectional study could not provide evidence for causality but only for associations.

Conclusion

Diagnostic delay, high economic burden and limited access to specific treatments are associated with low HRQoL of MPS patients and are common challenges faces by MPS patients in China. Findings of this study highlight the need to improve early detection and diagnosis, create fair and consistent mechanisms to increase access to specialized treatment, reduce the economic burden and improve HRQoL of MPS patients in China. In addition to strengthen training and cooperation among the NCDTRD, which play a key role in addressing rare disease issues in diagnosis, management and treatment, substantial efforts are urgently needed to deal with the availability and affordability of specialized treatment for MPS patients. For example, improving perinatal genetic screening for rare diseases and including related costs in maternity insurance, developing multi-party healthcare payment schemes and establishing a special fund with the participation of government, commercial companies, charities and patients, encouraging donated drug projects, and setting-up a differentiated registration and approval system for orphan drugs, increase public and government awareness of rare diseases.

Acknowledgements

We would like to thank Shanghai Foundation for Rare Disease, Rare Disease Society of Shanghai Medical Association, Pediatric Society of Chinese Medical Association for coordination of the study. We would also like to thank the Beijing Zhengyu MPS Care Center for assistance in recruiting the participants.

Author contributions

Qi Kang and Yuhang Fang contributed equally to this manuscript. Yan Yang and Xinyi Chen organized and analyzed the data. Dingguo Li and Lin Zheng provided comments on the data analysis. Xiaowen Tu and Chunlin Jin edited the manuscript and provided corrections.

Funding

The survey was supported by Sanofi China, CANbridge Pharmaceuticals Inc. and Biomarin Pharmaceuticals Inc. The analysis was supported by Health Young Talent Program from Shanghai Health Commission (2022YQ058).

Availability of data and materials

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non‑commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Declarations

Ethics approval and consent to participate

The study was approved by the Medical Ethics Committee of Shanghai Health Development Research Center.

Consent for publication

The manuscript has not been published previously, and it is not under consideration for publication elsewhere. All the authors had complete access to the manuscript and agreed to submit it for publication.

Competing interests

The authors have no conflicts of interest to disclose.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Qi Kang and Yuhang Fang have contributed equally to this work.
==== Refs
References

1. Okur I Ezgu F Giugliani R Muschol N Koehn A Amartino H Longitudinal natural history of pediatric subjects affected with mucopolysaccharidosis IIIB J Pediatr 2022 249 50 58 10.1016/j.jpeds.2022.06.005 35709957
Okur I, Ezgu F, Giugliani R, Muschol N, Koehn A, Amartino H, et al. Longitudinal natural history of pediatric subjects affected with mucopolysaccharidosis IIIB. J Pediatr. 2022;249:50–8.35709957 10.1016/j.jpeds.2022.06.005
2. Nagpal R Goyal RB Priyadarshini K Kashyap S Sharma M Sinha R Mucopolysaccharidosis: a broad review Indian J Ophthalmol 2022 70 2249 2261 10.4103/ijo.IJO_425_22 35791104
Nagpal R, Goyal RB, Priyadarshini K, Kashyap S, Sharma M, Sinha R, et al. Mucopolysaccharidosis: a broad review. Indian J Ophthalmol. 2022;70:2249–61.35791104 10.4103/ijo.IJO_425_22
3. Chen X Qiu W Ye J Han L Gu X Zhang H Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China J Hum Genet 2016 61 345 349 10.1038/jhg.2015.155 26740238
Chen X, Qiu W, Ye J, Han L, Gu X, Zhang H. Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China. J Hum Genet. 2016;61:345–9.26740238 10.1038/jhg.2015.155
4. Zhou J Lin J Leung WT Wang L A basic understanding of mucopolysaccharidosis: incidence, clinical features, diagnosis, and management Intractable Rare Dis Res 2020 9 1 9 10.5582/irdr.2020.01011 32201668
Zhou J, Lin J, Leung WT, Wang L. A basic understanding of mucopolysaccharidosis: incidence, clinical features, diagnosis, and management. Intractable Rare Dis Res. 2020;9:1–9.32201668 10.5582/irdr.2020.01011
5. Celik B Tomatsu SC Tomatsu S Khan SA Epidemiology of mucopolysaccharidoses update Diagnostics (Basel) 2021 11 273 10.3390/diagnostics11020273 33578874
Celik B, Tomatsu SC, Tomatsu S, Khan SA. Epidemiology of mucopolysaccharidoses update. Diagnostics (Basel). 2021;11:273.33578874 10.3390/diagnostics11020273
6. Al-Maawali AA Joshi SN Koul RL Al-Maawali AA Al-Sedari HS Al-Amri BM Spectrum of paediatric lysosomal storage disorders in oman Sultan Qaboos Univ Med J 2012 12 295 299 10.12816/0003142 22912921
Al-Maawali AA, Joshi SN, Koul RL, Al-Maawali AA, Al-Sedari HS, Al-Amri BM, et al. Spectrum of paediatric lysosomal storage disorders in oman. Sultan Qaboos Univ Med J. 2012;12:295–9.22912921 10.12816/0003142
7. Puckett Y Mallorga-Hernandez A Montano AM Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities Orphanet J Rare Dis 2021 16 241 10.1186/s13023-021-01880-8 34051828
Puckett Y, Mallorga-Hernandez A, Montano AM. Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges and opportunities. Orphanet J Rare Dis. 2021;16:241.34051828 10.1186/s13023-021-01880-8
8. Lin HY Lin SP Chuang CK Niu DM Chen MR Tsai FJ Incidence of the mucopolysaccharidoses in Taiwan, 1984–2004 Am J Med Genet A 2009 149A 960 964 10.1002/ajmg.a.32781 19396827
Lin HY, Lin SP, Chuang CK, Niu DM, Chen MR, Tsai FJ, et al. Incidence of the mucopolysaccharidoses in Taiwan, 1984–2004. Am J Med Genet A. 2009;149A:960–4.19396827 10.1002/ajmg.a.32781
9. Morrison A Oussoren E Friedel T Cruz J Yilmaz N Pathway to diagnosis and burden of illness in mucopolysaccharidosis type VII—a European caregiver survey Orphanet J Rare Dis 2019 14 254 10.1186/s13023-019-1233-z 31727109
Morrison A, Oussoren E, Friedel T, Cruz J, Yilmaz N. Pathway to diagnosis and burden of illness in mucopolysaccharidosis type VII—a European caregiver survey. Orphanet J Rare Dis. 2019;14:254.31727109 10.1186/s13023-019-1233-z
10. Kuiper GA Meijer O Langereis EJ Wijburg FA Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications Orphanet J Rare Dis 2018 13 2 10.1186/s13023-017-0733-y 29310675
Kuiper GA, Meijer O, Langereis EJ, Wijburg FA. Failure to shorten the diagnostic delay in two ultra-orphan diseases (mucopolysaccharidosis types I and III): potential causes and implications. Orphanet J Rare Dis. 2018;13:2.29310675 10.1186/s13023-017-0733-y
11. Grewal M Muranjan M Diagnosis is in the eye of the beholder: barriers to early diagnosis of mucopolysaccharidosis in children in India J Pediatr Genet 2021 10 300 304 10.1055/s-0040-1716707 34849275
Grewal M, Muranjan M. Diagnosis is in the eye of the beholder: barriers to early diagnosis of mucopolysaccharidosis in children in India. J Pediatr Genet. 2021;10:300–4.34849275 10.1055/s-0040-1716707
12. Vieira T Schwartz I Munoz V Pinto L Steiner C Ribeiro M Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis? Am J Med Genet A 2008 146A 1741 1747 10.1002/ajmg.a.32320 18546277
Vieira T, Schwartz I, Munoz V, Pinto L, Steiner C, Ribeiro M, et al. Mucopolysaccharidoses in Brazil: what happens from birth to biochemical diagnosis? Am J Med Genet A. 2008;146A:1741–7.18546277 10.1002/ajmg.a.32320
13. Colmenares-Bonilla D Esquitin-Garduno N Diagnosis of Morquio-A patients in Mexico: How far are we from prompt diagnosis? Intractable Rare Dis Res 2017 6 119 123 10.5582/irdr.2017.01016 28580212
Colmenares-Bonilla D, Esquitin-Garduno N. Diagnosis of Morquio-A patients in Mexico: How far are we from prompt diagnosis? Intractable Rare Dis Res. 2017;6:119–23.28580212 10.5582/irdr.2017.01016
14. Jones SA Almassy Z Beck M Burt K Clarke JT Giugliani R Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS) J Inherit Metab Dis 2009 32 534 543 10.1007/s10545-009-1119-7 19597960
Jones SA, Almassy Z, Beck M, Burt K, Clarke JT, Giugliani R, et al. Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis. 2009;32:534–43.19597960 10.1007/s10545-009-1119-7
15. Lisi EC Gillespie S Laney D Ali N Patients' perspectives on newborn screening for later-onset lysosomal storage diseases Mol Genet Metab 2016 119 109 114 10.1016/j.ymgme.2016.07.009 27591925
Lisi EC, Gillespie S, Laney D, Ali N. Patients’ perspectives on newborn screening for later-onset lysosomal storage diseases. Mol Genet Metab. 2016;119:109–14.27591925 10.1016/j.ymgme.2016.07.009
16. de Ru MH Bouwman MG Wijburg FA van Zwieten MC Experiences of parents and patients with the timing of Mucopolysaccharidosis type I (MPS I) diagnoses and its relevance to the ethical debate on newborn screening Mol Genet Metab 2012 107 501 507 10.1016/j.ymgme.2012.08.008 22926196
de Ru MH, Bouwman MG, Wijburg FA, van Zwieten MC. Experiences of parents and patients with the timing of Mucopolysaccharidosis type I (MPS I) diagnoses and its relevance to the ethical debate on newborn screening. Mol Genet Metab. 2012;107:501–7.22926196 10.1016/j.ymgme.2012.08.008
17. Zurynski Y Deverell M Dalkeith T Johnson S Christodoulou J Leonard H Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays Orphanet J Rare Dis 2017 12 68 10.1186/s13023-017-0622-4 28399928
Zurynski Y, Deverell M, Dalkeith T, Johnson S, Christodoulou J, Leonard H, et al. Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays. Orphanet J Rare Dis. 2017;12:68.28399928 10.1186/s13023-017-0622-4
18. Gaffke L Pierzynowska K Podlacha M Brokowska J Wegrzyn G Changes in cellular processes occurring in mucopolysaccharidoses as underestimated pathomechanisms of these diseases Cell Biol Int 2021 45 498 506 10.1002/cbin.11275 31855304
Gaffke L, Pierzynowska K, Podlacha M, Brokowska J, Wegrzyn G. Changes in cellular processes occurring in mucopolysaccharidoses as underestimated pathomechanisms of these diseases. Cell Biol Int. 2021;45:498–506.31855304 10.1002/cbin.11275
19. Brunelli MJ Atallah ÁN Da SE Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI Cochrane Database Syst Rev 2021 9 D9806
Brunelli MJ, Atallah ÁN, Da SE. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI. Cochrane Database Syst Rev. 2021;9:D9806.
20. McCafferty EH Scott LJ Vestronidase Alfa: a review in mucopolysaccharidosis VII BioDrugs 2019 33 233 240 10.1007/s40259-019-00344-7 30848434
McCafferty EH, Scott LJ. Vestronidase Alfa: a review in mucopolysaccharidosis VII. BioDrugs. 2019;33:233–40.30848434 10.1007/s40259-019-00344-7
21. Sawamoto K Álvarez GJ Piechnik M Otero FJ Couce ML Suzuki Y Mucopolysaccharidosis IVA: diagnosis, treatment, and management Int J Mol Sci 2020 21 1517 10.3390/ijms21041517 32102177
Sawamoto K, Álvarez GJ, Piechnik M, Otero FJ, Couce ML, Suzuki Y, et al. Mucopolysaccharidosis IVA: diagnosis, treatment, and management. Int J Mol Sci. 2020;21:1517.32102177 10.3390/ijms21041517
22. Hampe CS Wesley J Lund TC Orchard PJ Polgreen LE Eisengart JB Mucopolysaccharidosis type I: current treatments, limitations, and prospects for improvement Biomolecules 2021 11 189 10.3390/biom11020189 33572941
Hampe CS, Wesley J, Lund TC, Orchard PJ, Polgreen LE, Eisengart JB, et al. Mucopolysaccharidosis type I: current treatments, limitations, and prospects for improvement. Biomolecules. 2021;11:189.33572941 10.3390/biom11020189
23. Franco J El DR Agarwal A Soares D Milhan N Albano L Mucopolysaccharidosis type I, II and VI and response to enzyme replacement therapy: results from a single-center case series study Intractable Rare Dis Res 2017 6 183 190 10.5582/irdr.2017.01036 28944140
Franco J, El DR, Agarwal A, Soares D, Milhan N, Albano L, et al. Mucopolysaccharidosis type I, II and VI and response to enzyme replacement therapy: results from a single-center case series study. Intractable Rare Dis Res. 2017;6:183–90.28944140 10.5582/irdr.2017.01036
24. Aldenhoven M Wynn RF Orchard PJ O'Meara A Veys P Fischer A Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study Blood 2015 125 2164 2172 10.1182/blood-2014-11-608075 25624320
Aldenhoven M, Wynn RF, Orchard PJ, O’Meara A, Veys P, Fischer A, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125:2164–72.25624320 10.1182/blood-2014-11-608075
25. Braun SE Pan D Aronovich EL Jonsson JJ McIvor RS Whitley CB Preclinical studies of lymphocyte gene therapy for mild Hunter syndrome (mucopolysaccharidosis type II) Hum Gene Ther 1996 7 283 290 10.1089/hum.1996.7.3-283 8835216
Braun SE, Pan D, Aronovich EL, Jonsson JJ, McIvor RS, Whitley CB. Preclinical studies of lymphocyte gene therapy for mild Hunter syndrome (mucopolysaccharidosis type II). Hum Gene Ther. 1996;7:283–90.8835216 10.1089/hum.1996.7.3-283
26. Kanters TA Redekop WK Hakkaart L International differences in patient access to ultra-orphan drugs Health Policy Technol 2018 7 57 64 10.1016/j.hlpt.2017.12.001
Kanters TA, Redekop WK, Hakkaart L. International differences in patient access to ultra-orphan drugs. Health Policy Technol. 2018;7:57–64.10.1016/j.hlpt.2017.12.001
27. Frost & Sullivan, Illness Challenge Foundation. Watch Report: 2023 China Rare Disease Industry Trend[In Chinese]. 2023.
28. Hu J Zhu L He J Li D Kang Q Jin C The usage of enzyme replacement treatments, economic burden, and quality of life of patients with four lysosomal storage diseases in Shanghai, China Intractable Rare Dis Res 2021 10 190 197 10.5582/irdr.2021.01091 34466341
Hu J, Zhu L, He J, Li D, Kang Q, Jin C. The usage of enzyme replacement treatments, economic burden, and quality of life of patients with four lysosomal storage diseases in Shanghai, China. Intractable Rare Dis Res. 2021;10:190–7.34466341 10.5582/irdr.2021.01091
29. Adachi T El-Hattab AW Jain R Nogales CK Quirland LC Scarpa M Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges Int J Environ Res Public Health 2023 20 4732 10.3390/ijerph20064732 36981643
Adachi T, El-Hattab AW, Jain R, Nogales CK, Quirland LC, Scarpa M, et al. Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges. Int J Environ Res Public Health. 2023;20:4732.36981643 10.3390/ijerph20064732
30. Dong D Wang Y Challenges of rare diseases in China Lancet 2016 387 1906 10.1016/S0140-6736(16)30418-4 27203652
Dong D, Wang Y. Challenges of rare diseases in China. Lancet. 2016;387:1906.27203652 10.1016/S0140-6736(16)30418-4
31. Chung CCY Ng NYT Ng YNC Lui ACY Fung JLF Chan MCY Socio-economic costs of rare diseases and the risk of financial hardship: a cross-sectional study Lancet Reg Health Western Pac 2023 34 100711 10.1016/j.lanwpc.2023.100711
Chung CCY, Ng NYT, Ng YNC, Lui ACY, Fung JLF, Chan MCY, et al. Socio-economic costs of rare diseases and the risk of financial hardship: a cross-sectional study. Lancet Reg Health Western Pac. 2023;34:100711.10.1016/j.lanwpc.2023.100711
32. Guffon N Heron B Chabrol B Feillet F Montauban V Valayannopoulos V Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study Orphanet J Rare Dis 2015 10 43 10.1186/s13023-015-0259-0 25887606
Guffon N, Heron B, Chabrol B, Feillet F, Montauban V, Valayannopoulos V. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study. Orphanet J Rare Dis. 2015;10:43.25887606 10.1186/s13023-015-0259-0
33. Brands MM Gungor D van den Hout JM Karstens FP Oussoren E Plug I Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey J Inherit Metab Dis 2015 38 323 331 10.1007/s10545-014-9737-0 25048386
Brands MM, Gungor D, van den Hout JM, Karstens FP, Oussoren E, Plug I, et al. Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey. J Inherit Metab Dis. 2015;38:323–31.25048386 10.1007/s10545-014-9737-0
34. Quijada-Fraile P Arranz CE Martin-Hernandez E Ballesta-Martinez MJ Guillen-Navarro E Pintos-Morell G Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience Orphanet J Rare Dis 2021 16 464 10.1186/s13023-021-02074-y 34732228
Quijada-Fraile P, Arranz CE, Martin-Hernandez E, Ballesta-Martinez MJ, Guillen-Navarro E, Pintos-Morell G, et al. Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience. Orphanet J Rare Dis. 2021;16:464.34732228 10.1186/s13023-021-02074-y
35. Conner T Cook F Fernandez V Rascati K Rangel-Miller V An online survey on burden of illness among families with post-stem cell transplant mucopolysaccharidosis type I children in the United States Orphanet J Rare Dis 2019 14 48 10.1186/s13023-019-1027-3 30777108
Conner T, Cook F, Fernandez V, Rascati K, Rangel-Miller V. An online survey on burden of illness among families with post-stem cell transplant mucopolysaccharidosis type I children in the United States. Orphanet J Rare Dis. 2019;14:48.30777108 10.1186/s13023-019-1027-3
36. Shapiro EG Rudser K Ahmed A Steiner RD Delaney KA Yund B A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II Mol Genet Metab Rep 2016 7 32 39 27114914
Shapiro EG, Rudser K, Ahmed A, Steiner RD, Delaney KA, Yund B, et al. A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II. Mol Genet Metab Rep. 2016;7:32–9.27114914
37. Pentek M Gulacsi L Brodszky V Baji P Boncz I Pogany G Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe Eur J Health Econ 2016 17 Suppl 1 89 98 10.1007/s10198-016-0787-0 27062257
Pentek M, Gulacsi L, Brodszky V, Baji P, Boncz I, Pogany G, et al. Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. Eur J Health Econ. 2016;17(Suppl 1):89–98.27062257 10.1007/s10198-016-0787-0
38. Raluy-Callado M Chen WH Whiteman DA Fang J Wiklund I The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life Orphanet J Rare Dis 2013 8 101 10.1186/1750-1172-8-101 23837440
Raluy-Callado M, Chen WH, Whiteman DA, Fang J, Wiklund I. The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life. Orphanet J Rare Dis. 2013;8:101.23837440 10.1186/1750-1172-8-101
39. Needham M Packman W Quinn N Rappoport M Aoki C Bostrom A Health-related quality of life in patients with MPS II J Genet Couns 2015 24 635 644 10.1007/s10897-014-9791-7 25395377
Needham M, Packman W, Quinn N, Rappoport M, Aoki C, Bostrom A, et al. Health-related quality of life in patients with MPS II. J Genet Couns. 2015;24:635–44.25395377 10.1007/s10897-014-9791-7
40. Hendriksz CJ Lavery C Coker M Ucar SK Jain M Bell L Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey Orphanet J Rare Dis 2014 9 32 10.1186/1750-1172-9-32 24602160
Hendriksz CJ, Lavery C, Coker M, Ucar SK, Jain M, Bell L, et al. Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey. Orphanet J Rare Dis. 2014;9:32.24602160 10.1186/1750-1172-9-32
41. Varni JW Seid M Kurtin PS PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations Med Care 2001 39 800 812 10.1097/00005650-200108000-00006 11468499
Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001;39:800–12.11468499 10.1097/00005650-200108000-00006
42. Yiyun L Qi T Yuantao H Jin J Yudeng L Dingqun H Reliability and validity for Chinese version of pediatric quality of life inventory PedsQL4.0[In Chinese] J Sun Yat-Sen Univ (Med Sci) 2008 29 328 331
Yiyun L, Qi T, Yuantao H, Jin J, Yudeng L, Dingqun H. Reliability and validity for Chinese version of pediatric quality of life inventory PedsQL4.0[In Chinese]. J Sun Yat-Sen Univ (Med Sci). 2008;29:328–31.
43. Ware JJ Sherbourne CD The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection Med Care 1992 30 473 483 10.1097/00005650-199206000-00002 1593914
Ware JJ, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–83.1593914 10.1097/00005650-199206000-00002
44. Ren XS Amick BR Zhou L Gandek B Translation and psychometric evaluation of a Chinese version of the SF-36 Health Survey in the United States J Clin Epidemiol 1998 51 1129 1138 10.1016/S0895-4356(98)00104-8 9817130
Ren XS, Amick BR, Zhou L, Gandek B. Translation and psychometric evaluation of a Chinese version of the SF-36 Health Survey in the United States. J Clin Epidemiol. 1998;51:1129–38.9817130 10.1016/S0895-4356(98)00104-8
45. Li L Wang HM Shen Y Chinese SF-36 Health Survey: translation, cultural adaptation, validation, and normalisation J Epidemiol Community Health 2003 57 259 263 10.1136/jech.57.4.259 12646540
Li L, Wang HM, Shen Y. Chinese SF-36 Health Survey: translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health. 2003;57:259–63.12646540 10.1136/jech.57.4.259
46. Ware J Snoww K Kosinski M Gandek B SF-36 Health Survey: manual and interpretation guide Boston 1993 Massachusetts Nimrod Press
Ware J, Snoww K, Kosinski M, Gandek B. SF-36 Health Survey: manual and interpretation guide Boston. Massachusetts: Nimrod Press; 1993.
47. Tinfang P Chaozeng S Huijing H Bin W Guangliang S Survey of health-related quality of life in population of 6 Chinese cities[In Chinese] Basic Clin Med 2011 31 636 641
Tinfang P, Chaozeng S, Huijing H, Bin W, Guangliang S. Survey of health-related quality of life in population of 6 Chinese cities[In Chinese]. Basic Clin Med. 2011;31:636–41.
48. Viberg N Forsberg BC Borowitz M Molin R International comparisons of waiting times in health care–limitations and prospects Health Policy 2013 112 53 61 10.1016/j.healthpol.2013.06.013 23895881
Viberg N, Forsberg BC, Borowitz M, Molin R. International comparisons of waiting times in health care–limitations and prospects. Health Policy. 2013;112:53–61.23895881 10.1016/j.healthpol.2013.06.013
49. Qi X Xu J Shan L Li Y Cui Y Liu H Economic burden and health related quality of life of ultra-rare Gaucher disease in China Orphanet J Rare Dis 2021 16 358 10.1186/s13023-021-01963-6 34380529
Qi X, Xu J, Shan L, Li Y, Cui Y, Liu H, et al. Economic burden and health related quality of life of ultra-rare Gaucher disease in China. Orphanet J Rare Dis. 2021;16:358.34380529 10.1186/s13023-021-01963-6
50. National Bureau of Statistics. Resident Income and Consumer Spending in 2022[In Chinese]. In 2023.
51. Tylki-Szymanska A Almassy Z Christophidou-Anastasiadou V Avdjieva-Tzavella D Barisic I Cerkauskiene R The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers Orphanet J Rare Dis 2022 17 136 10.1186/s13023-022-02285-x 35331284
Tylki-Szymanska A, Almassy Z, Christophidou-Anastasiadou V, Avdjieva-Tzavella D, Barisic I, Cerkauskiene R, et al. The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers. Orphanet J Rare Dis. 2022;17:136.35331284 10.1186/s13023-022-02285-x
52. Red Cross Society of China, Shanghai Branch. Including disease-specific therapies for LSDs in the payment range of Shanghai Children's Hospitalization Assistance Fund[In Chinese]. In 2011.
53. Shanghai Municipal Bureau of Medical Security. Product Manuals of "Shanghai Beneficial Insurance"[In Chinese]. In 2021.
54. Schlander M Beck M Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI Curr Med Res Opin 2009 25 1285 1293 10.1185/03007990902892633 19366306
Schlander M, Beck M. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin. 2009;25:1285–93.19366306 10.1185/03007990902892633
55. Heard JM Vrinten C Schlander M Bellettato CM van Lingen C Scarpa M Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network Orphanet J Rare Dis 2020 15 3 10.1186/s13023-019-1280-5 31907071
Heard JM, Vrinten C, Schlander M, Bellettato CM, van Lingen C, Scarpa M. Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network. Orphanet J Rare Dis. 2020;15:3.31907071 10.1186/s13023-019-1280-5
56. Davari M Nabizadeh A Kadivar M Abdollahi AA Healthcare resource utilization and the cost of care for mucopolysaccharidosis I patients in Iran Value Health Reg Issues 2019 18 165 169 10.1016/j.vhri.2019.01.009 31082797
Davari M, Nabizadeh A, Kadivar M, Abdollahi AA. Healthcare resource utilization and the cost of care for mucopolysaccharidosis I patients in Iran. Value Health Reg Issues. 2019;18:165–9.31082797 10.1016/j.vhri.2019.01.009
57. Meijer SA Sinnema G Bijstra JO Mellenbergh GJ Wolters WH Social functioning in children with a chronic illness J Child Psychol Psychiatry 2000 41 309 317 10.1111/1469-7610.00615 10784078
Meijer SA, Sinnema G, Bijstra JO, Mellenbergh GJ, Wolters WH. Social functioning in children with a chronic illness. J Child Psychol Psychiatry. 2000;41:309–17.10784078 10.1111/1469-7610.00615
58. Lemos CF Rodrigues MP Veiga JR Family income is associated with quality of life in patients with chronic kidney disease in the pre-dialysis phase: a cross sectional study Health Qual Life Outcomes 2015 13 202 10.1186/s12955-015-0390-6 26690667
Lemos CF, Rodrigues MP, Veiga JR. Family income is associated with quality of life in patients with chronic kidney disease in the pre-dialysis phase: a cross sectional study. Health Qual Life Outcomes. 2015;13:202.26690667 10.1186/s12955-015-0390-6
59. Bogart KR Irvin VL Health-related quality of life among adults with diverse rare disorders Orphanet J Rare Dis 2017 12 177 10.1186/s13023-017-0730-1 29212508
Bogart KR, Irvin VL. Health-related quality of life among adults with diverse rare disorders. Orphanet J Rare Dis. 2017;12:177.29212508 10.1186/s13023-017-0730-1
60. Ando H Cousins R Young CA Understanding quality of life across different clinical subtypes of multiple sclerosis: a thematic analysis Qual Life Res 2022 31 2035 2046 10.1007/s11136-021-03041-7 34822047
Ando H, Cousins R, Young CA. Understanding quality of life across different clinical subtypes of multiple sclerosis: a thematic analysis. Qual Life Res. 2022;31:2035–46.34822047 10.1007/s11136-021-03041-7
61. Duan C Ai D Xu Q Sui B Zhao K Assessment of health-related quality of life in patients with spina muscular atrophy in China Intractable Rare Dis Res 2022 11 189 195 10.5582/irdr.2022.01094 36457580
Duan C, Ai D, Xu Q, Sui B, Zhao K. Assessment of health-related quality of life in patients with spina muscular atrophy in China. Intractable Rare Dis Res. 2022;11:189–95.36457580 10.5582/irdr.2022.01094
62. Coutinho MF Lacerda L Alves S Alaniz L Glycosaminoglycan storage disorders: a review Biochem Res Int 2012 2012 471325 10.1155/2012/471325 22013531
Coutinho MF, Lacerda L, Alves S, Alaniz L. Glycosaminoglycan storage disorders: a review. Biochem Res Int. 2012;2012:471325.22013531 10.1155/2012/471325
63. National Health Commission. The Guidelines for the Diagnosis and Treatment of Rare Diseases (2019 edition)[In Chinese]. In 2019.
64. Parini R Deodato F Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations Int J Mol Sci 2020 21 2975 10.3390/ijms21082975 32340185
Parini R, Deodato F. Intravenous enzyme replacement therapy in mucopolysaccharidoses: clinical effectiveness and limitations. Int J Mol Sci. 2020;21:2975.32340185 10.3390/ijms21082975
65. Wang J Luan Z Jiang H Fang J Qin M Lee V Allogeneic hematopoietic stem cell transplantation in thirty-four pediatric cases of mucopolysaccharidosis-a ten-year report from the china children transplant group Biol Blood Marrow Transpl 2016 22 2104 2108 10.1016/j.bbmt.2016.08.015
Wang J, Luan Z, Jiang H, Fang J, Qin M, Lee V, et al. Allogeneic hematopoietic stem cell transplantation in thirty-four pediatric cases of mucopolysaccharidosis-a ten-year report from the china children transplant group. Biol Blood Marrow Transpl. 2016;22:2104–8.10.1016/j.bbmt.2016.08.015
66. Akyol MU Alden TD Amartino H Ashworth J Belani K Berger KI Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance Orphanet J Rare Dis 2019 14 118 10.1186/s13023-019-1080-y 31142378
Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, et al. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance. Orphanet J Rare Dis. 2019;14:118.31142378 10.1186/s13023-019-1080-y
67. Ahn J Lee JJ Park SI Cho SY Jin DK Cho YS Auditory characteristics in patients with mucopolysaccharidosis Otol Neurotol 2019 40 e955 e961 10.1097/MAO.0000000000002422 31634273
Ahn J, Lee JJ, Park SI, Cho SY, Jin DK, Cho YS, et al. Auditory characteristics in patients with mucopolysaccharidosis. Otol Neurotol. 2019;40:e955–61.31634273 10.1097/MAO.0000000000002422
68. Bernardo FB de Sousa DD Oliveira TG Cavalcanti GD Reinaux C Dornelas DAA Functioning profiles of individuals with Mucopolysaccharidosis according to the International Classification of Functioning Eur J Phys Rehabil Med 2022 58 127 136 34468112
Bernardo FB, de Sousa DD, Oliveira TG, Cavalcanti GD, Reinaux C, Dornelas DAA. Functioning profiles of individuals with Mucopolysaccharidosis according to the International Classification of Functioning. Eur J Phys Rehabil Med. 2022;58:127–36.34468112
69. Dusing SC Thorpe D Rosenberg A Mercer V Escolar ML Gross motor abilities in children with Hurler syndrome Dev Med Child Neurol 2006 48 11 927 930 10.1111/j.1469-8749.2006.02027a.x 17044963
Dusing SC, Thorpe D, Rosenberg A, Mercer V, Escolar ML. Gross motor abilities in children with Hurler syndrome. Dev Med Child Neurol. 2006;48(11):927–30.17044963 10.1111/j.1469-8749.2006.02027a.x
70. Bicalho CG de Araújo LE de Andrade ÁM Acosta AX Hearing loss in mucopolysaccharidosis Int Arch Otorhinolaryngol 2021 25 e386 e391 10.1055/s-0040-1712107 34377173
Bicalho CG, de Araújo LE, de Andrade ÁM, Acosta AX. Hearing loss in mucopolysaccharidosis. Int Arch Otorhinolaryngol. 2021;25:e386–91.34377173 10.1055/s-0040-1712107
